EMEA-001475-PIP02-13-M02
Table of contents
Key facts
| Active substance |
Maralixibat chloride
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0298/2022
|
| PIP number |
EMEA-001475-PIP02-13-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Alagille syndrome
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Mirum Pharmaceuticals
E-mail: medinfo@mirumpharma.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|